Entera Bio (ENTX) Change in Account Payables (2021 - 2026)

Entera Bio (ENTX) has reported Change in Account Payables for 6 consecutive years, with -$174000.0 the latest figure, recorded in Q1 2026.

• Quarterly Change in Account Payables fell 8800.0% year-over-year to -$174000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140000.0 (up 105.88% YoY) and the FY2025 annual result came in at $316000.0, up 544.9% from the prior year.
• Change in Account Payables eased to -$174000.0 in Q1 2026 per ENTX's latest filing, from $232000.0 in the prior quarter.
• Over the last five years, Change in Account Payables for ENTX reached as high as $324000.0 in Q3 2023 and fell as low as -$481000.0 in Q4 2023.
• A 5-year average of $6352.9 and a median of $3000.0 in 2024 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2025 — Change in Account Payables soared 8200.0% — and 2026, when it plunged 8800.0%.
• Year by year, Change in Account Payables stood at -$396000.0 in 2022, then slipped by 21.46% to -$481000.0 in 2023, then surged by 89.19% to -$52000.0 in 2024, then jumped by 546.15% to $232000.0 in 2025, then slumped by 175.0% to -$174000.0 in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$174000.0, $232000.0, and -$167000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.